

Guillermo N Armaiz-Pena

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6741146/guillermo-n-armaiz-pena-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

4,973
citations

36
h-index

70
g-index

90
ext. papers

5,712
ext. citations

10.5
avg, IF

4.4
L-index

#	Paper	IF	Citations
60	Brief Report: Hispanic Patients' Trajectory of Cancer Symptom Burden, Depression, Anxiety, and Quality of Life.. <i>Nursing Reports</i> , 2021 , 11, 475-483	0.8	2
59	Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. <i>Scientific Reports</i> , 2021 , 11, 14334	4.9	0
58	E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer. <i>Experimental Biology and Medicine</i> , 2021 , 246, 2057-2071	3.7	0
57	Editorial Note: Targeting Src in Mucinous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4450	12.9	
56	Editorial Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4454	12.9	
55	Editorial Note: Functional Roles of and in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4452	12.9	
54	Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
53	Impact of a natural disaster on access to care and biopsychosocial outcomes among Hispanic/Latino cancer survivors. <i>Scientific Reports</i> , 2020 , 10, 10376	4.9	2
52	Catecholamine-Induced DNA Damage in Ovarian Cancer Cells. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
51	Zoledronic Acid Abrogates Restraint Stress-Induced Macrophage Infiltration, PDGF-AA Expression, and Ovarian Cancer Growth. <i>Cancers</i> , 2020 , 12,	6.6	6
50	Neuroendocrine Regulation of Tumor-Associated Immune Cells. <i>Frontiers in Oncology</i> , 2019 , 9, 1077	5.3	14
49	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018 , 78, 3233-3242	10.1	46
48	Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico. <i>BMC Cancer</i> , 2018 , 18, 1177	4.8	2
47	Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. <i>Scientific Reports</i> , 2018 , 8, 8291	4.9	6
46	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	7
45	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. <i>Clinical Cancer Research</i> , 2017 , 23, 7034-7046	12.9	52
44	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. <i>JCI Insight</i> , 2017 , 2,	9.9	20

43	Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. <i>Oncogene</i> , 2016 , 35, 2390-7	9.2	51
42	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016 , 7, 11169	17.4	83
41	Role of Increased n-acetylaspartate Levels in Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djv426	9.7	32
40	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. <i>Oncogene</i> , 2016 , 35, 4312-20	9.2	70
39	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1713-24	12.9	47
38	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1885-96	15.9	68
37	SSRI use and clinical outcomes in epithelial ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 33179-91	3.3	18
36	Targeting c-MYC in Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2260-9	6.1	68
35	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 19-40	9.6	62
34	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1466-1475	6.1	11
33	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015 , 28, 610-622	24.3	60
32	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2677-86	6.1	8
31	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015 , 13, 2395-2402	10.6	75
30	Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. <i>Oncotarget</i> , 2015 , 6, 4266-73	3.3	56
29	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014 , 5, 5202	17.4	130
28	2'OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014 , 5, 3459	17.4	81
27	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. <i>Nature Communications</i> , 2014 , 5, 5092	17.4	79
26	Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2583-94	6.1	21

25	Monocyte subpopulations in angiogenesis. <i>Cancer Research</i> , 2014 , 74, 1287-93	10.1	48
24	Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 919-29	4.6	33
23	Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. <i>Molecular Systems Biology</i> , 2014 , 10, 728	12.2	178
22	Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1750-7	6.1	23
21	Neuroendocrine influences on cancer progression. <i>Brain, Behavior, and Immunity</i> , 2013 , 30 Suppl, S19-25	16.6	89
20	Src activation by β adrenoreceptors is a key switch for tumour metastasis. <i>Nature Communications</i> , 2013 , 4, 1403	17.4	141
19	Why stress is BAD for cancer patients. <i>Journal of Clinical Investigation</i> , 2013 , 123, 558-60	15.9	12
18	Paraneoplastic thrombocytosis in ovarian cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 610-8	59.2	505
17	Targeting SRC in mucinous ovarian carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 5367-78	12.9	38
16	Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1596-612	9.7	38
15	Functional roles of Src and Fgr in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 1713-21	12.9	57
14	Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1515-23	15.9	192
13	Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. <i>Journal of Biological Chemistry</i> , 2010 , 285, 35462-70	5.4	131
12	Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. <i>Cancer Biology and Therapy</i> , 2010 , 9, 176-82	4.6	56
11	Regulation of tumor angiogenesis by EZH2. <i>Cancer Cell</i> , 2010 , 18, 185-97	24.3	290
10	Surgical stress promotes tumor growth in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 2695-702	22.9	160
9	Estrous cycle modulates ovarian carcinoma growth. <i>Clinical Cancer Research</i> , 2009 , 15, 2971-8	12.9	30
8	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 3770-80	12.9	103

7	Functional significance of VEGFR-2 on ovarian cancer cells. <i>International Journal of Cancer</i> , 2009 , 124, 1045-53	7.5	100
6	Neuroendocrine modulation of cancer progression. <i>Brain, Behavior, and Immunity</i> , 2009 , 23, 10-5	16.6	95
5	Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. <i>Clinical Cancer Research</i> , 2008 , 14, 5437-46	12.9	58
4	Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. <i>Journal of Biological Chemistry</i> , 2007 , 282, 29919-26	5.4	108
3	Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. <i>Cancer Research</i> , 2007 , 67, 10389-96	10.1	119
2	Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. <i>Clinical Cancer Research</i> , 2007 , 13, 3423-30	12.9	337
1	Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. <i>Nature Medicine</i> , 2006 , 12, 939-44	50.5	836